Study title: A Phase I Study of the Safety, Tolerance and Phannacokinetics of Reconstituted Lyophilized MEDI-493, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus, Administered Intravenously at 15 mg/kg and 30 mg/kg in Children with a History of Prematurity or Bronchopulmonary Dysplasia
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Virus Diseases | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: palivizumab | |||||
| ATC code: | |||||
| Document link: palivizumab-mi-cp045.pdf | |||||
| Document date: 2013-07-25 | |||||
| Study number: Mi-cp045 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | - | - | |